The Netherlands Cancer Institute
Open enrollment with a later-stage pipeline tilt
According to ClinicalTrials.gov-derived indexes, The Netherlands Cancer Institute sits in the upper quartile of US sponsors by registered trial count (#3,661 of 15,742 sponsors by registered trial count).
The Netherlands Cancer Institute: 3 sponsored US clinical trials, 1 recruiting.
The Netherlands Cancer Institute sponsors 3 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 1 completed. 2 of these trials are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Malignant Melanoma Stage III, with 1 trials.
Upper-quartile sponsor footprint
The Netherlands Cancer Institute sits in the upper quartile of the sponsor corpus (#3,661 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
3 total, page 1 of 1
Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
NCT03772028
Neoadjuvant Ipilimumab Plus Nivolumab Versus Standard Adjuvant Nivolumab in Macroscopic Stage III Melanoma
NCT04949113
Irradiation of Large Lung Tumors or Two or More Lung Metastases Simultaneously
NCT01543672
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 3 | 2 |
Therapeutic Areas
Where The Netherlands Cancer Institute enrollment is open (later-stage tilt)
1 recruiting of 3 indexed (33% open); 1 completed (33%).
Phase mix: 2 late (III/IV) vs 1 early (I/II) (later-stage heavy).
Top condition: Malignant Melanoma Stage III (1 trial), 3 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
The Netherlands Cancer Institute: open-pipeline peers nationwide
Peers matched on 3 registered trials and 33% open enrollment, not the therapeutic-area sidebar.
The Netherlands Cancer Institute sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 3 trials (± recruiting share)
- 10xBio · 3 trials · 0% recruiting
- 22nd Century Group · 3 trials · 0% recruiting
- AA Secord · 3 trials · 0% recruiting
- AAADRS Clinical Research Center · 3 trials · 0% recruiting
Sponsors near 33% open enrollment (± trial volume)
- Aadi Bioscience · 33% recruiting · 9 trials
- Aaron Cook · 33% recruiting · 3 trials
- Abivax S.A. · 33% recruiting · 6 trials
- Actuated Medical · 33% recruiting · 3 trials
Related
What to do with this The Netherlands Cancer Institute page
3 registered trials is a research-attention snapshot, not an endorsement of The Netherlands Cancer Institute or any single study.
- 1 of The Netherlands Cancer Institute's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Malignant Melanoma Stage III is the condition The Netherlands Cancer Institute studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Malignant Melanoma Stage III trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
The Netherlands Cancer Institute pipeline card: 3 registered trials from official public datasets.Report a data error.